Did you mean aromatase inhibitor?
Displaying drugs 176 - 200 of 2435 in total
Tetracycline
Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the...
Approved
Vet approved
Withdrawn
Matched Categories: … Enzyme Inhibitors ... OAT1/SLC22A6 inhibitors ... OAT3/SLC22A8 Inhibitors ... Protein Synthesis Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Felodipine
Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB...
Approved
Investigational
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... ACE Inhibitors and Calcium Channel Blockers ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors …
Estradiol valerate
Estradiol Valerate (also known as E2V) is a pro-drug ester of DB00783, a naturally occurring hormone that circulates endogenously within the human body. Estradiol is the most potent form of all mammalian estrogenic steroids and acts as the major female sex hormone. As a pro-drug of estradiol, estradiol acetate therefore...
Approved
Investigational
Vet approved
Matched Categories: … BCRP/ABCG2 Inhibitors ... OCT1 inhibitors ... OCT2 Inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors …
Tafamidis
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... OAT1/SLC22A6 inhibitors ... OAT3/SLC22A8 Inhibitors …
Fosdenopterin
Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and aldehyde oxidase. Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.[A230088,L32163]...
Approved
Matched Categories: … MATE inhibitors ... MATE 2 Inhibitors ... OAT1/SLC22A6 inhibitors …
Baricitinib
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Categories: … MATE inhibitors ... BCRP/ABCG2 Inhibitors ... OCT2 Inhibitors ... MATE 2 Inhibitors ... OATP1B3 inhibitors …
Quinine
An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in...
Approved
Matched Categories: … OCT1 inhibitors ... OCT2 Inhibitors ... P-glycoprotein inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors …
Sulfasalazine
Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into mesalazine and sulfapyridine, 2 compounds that carry out the main pharmacological...
Approved
Matched Categories: … NTCP Inhibitors ... OATP1B3 inhibitors ... BCRP/ABCG2 Inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Organic Anion Transporting Polypeptide 2B1 Inhibitors …
Valdecoxib
Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke.
Approved
Investigational
Withdrawn
Matched Categories: … COX-2 Inhibitors ... Enzyme Inhibitors ... Cyclooxygenase Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors …
Didanosine
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral...
Approved
Matched Categories: … Enzyme Inhibitors ... Nucleic Acid Synthesis Inhibitors ... Reverse Transcriptase Inhibitors ... Nucleoside Reverse Transcriptase Inhibitors ... Nucleoside and Nucleotide Reverse Transcriptase Inhibitors …
Dextropropoxyphene
Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe...
Approved
Illicit
Investigational
Withdrawn
Matched Categories: … Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors (strength unknown) …
Lomitapide
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP3A Inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors (weak) …
Ambenonium
Ambenonium is a cholinesterase inhibitor. It is used in the management of myasthenia gravis.
Approved
Matched Categories: … Enzyme Inhibitors ... Cholinesterase Inhibitors …
Tacrolimus
Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis...
Approved
Investigational
Matched Categories: … Enzyme Inhibitors ... Calcineurin Inhibitors ... P-glycoprotein inhibitors ... OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors …
Cenobamate
Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.[A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels. Cenobamate was granted FDA approval on 21 November 2019.
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 CYP3A5 Inhibitors …
Fluticasone
Fluticasone is a synthetic glucocorticoid available as 2 esters, DB08906 and DB00588[F4355,F4358,F4361,F4364][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label]. DB00588 was first approved in 1990 and DB08906 was approved in 2007 .
Approved
Experimental
Matched Categories: … OATP1B1/SLCO1B1 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors ... Cytochrome P-450 CYP3A5 Inhibitors …
Olanzapine
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles clozapine and only differs by...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors …
Interferon alfa-n3
Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD).
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP1A2 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) …
Larotrectinib
Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and...
Approved
Investigational
Matched Categories: … Protein Kinase Inhibitors ... Tyrosine Kinase Inhibitors ... Tropomyosin Receptor Kinases Inhibitors …
Finasteride
Finasteride is a synthetic 4-azasteroid compound and specific inhibitor of steroid Type II 5α-reductase, which is an intracellular enzyme that converts the androgen testosterone into 5α-dihydrotestosterone (DHT). It works in a similar fashion as dutasteride, which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects. Finasteride is an orally active drug...
Approved
Matched Description: … Compared to alpha-blockers that focus on providing the rapid relief of symptoms, 5α-reductase inhibitors …
Matched Categories: … Enzyme Inhibitors ... 5-alpha Reductase Inhibitors ... Steroid Synthesis Inhibitors …
Matched Categories: … Enzyme Inhibitors ... 5-alpha Reductase Inhibitors ... Steroid Synthesis Inhibitors …
Taurocholic acid
The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.
Approved
Experimental
Matched Categories: … BCRP/ABCG2 Inhibitors ... OAT1/SLC22A6 inhibitors ... OAT3/SLC22A8 Inhibitors ... P-glycoprotein inhibitors ... OATP1B1/SLCO1B1 Inhibitors …
Palovarotene
Fibrodysplasia Ossificans Progressiva (FOP), with an estimated worldwide prevalence of one in 2 million individuals, is an exceptionally rare genetic disorder. FOP is caused by a gain-of-function mutation in the ACVR1/ALK2 gene which results in progressive heterotopic ossification, a process wherein connective tissues (e.g. skeletal muscle, ligaments, tendons) are replaced...
Approved
Investigational
Matched Categories: … BCRP/ABCG2 Inhibitors ... OCT1 inhibitors ... BSEP/ABCB11 Inhibitors ... OATP1B3 inhibitors ... OATP1B1/SLCO1B1 Inhibitors …
Flurazepam
A benzodiazepine derivative used mainly as a hypnotic.
Approved
Illicit
Investigational
Matched Categories: … OCT2 Inhibitors ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP2E1 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2E1 Inhibitors (strength unknown) …
Tazobactam
Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms. It is combined with Piperacillin and Ceftolozane for the treatment of a variety of bacterial infections.
Piperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved...
Approved
Matched Categories: … Enzyme Inhibitors ... beta-Lactamase Inhibitors ... OAT1/SLC22A6 inhibitors ... OAT3/SLC22A8 Inhibitors …
Ibrutinib
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in...
Approved
Matched Categories: … Enzyme Inhibitors ... Protein Kinase Inhibitors ... Tyrosine Kinase Inhibitors ... Bruton's tyrosine kinase (BTK) inhibitors …
Displaying drugs 176 - 200 of 2435 in total